The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP)
Purpose of Review We assess the literature on the pharmacokinetics, indications, important considerations, and effectiveness of long-term, low-dose macrolide antibiotics in chronic rhinosinusitis (CRS). Recent Findings The key to effective implementation of macrolide therapy in CRS is appropriate pa...
Gespeichert in:
| Veröffentlicht in: | Current allergy and asthma reports 2017-05, Vol.17 (5), p.30-30, Article 30 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 5 |
| container_start_page | 30 |
| container_title | Current allergy and asthma reports |
| container_volume | 17 |
| creator | Oakley, Gretchen M. Harvey, Richard J. Lund, Valerie J. |
| description | Purpose of Review
We assess the literature on the pharmacokinetics, indications, important considerations, and effectiveness of long-term, low-dose macrolide antibiotics in chronic rhinosinusitis (CRS).
Recent Findings
The key to effective implementation of macrolide therapy in CRS is appropriate patient selection. Macrolides have demonstrated the most benefit in Th1-mediated non-eosinophilic CRS when used for durations of at least 3 months.
Summary
Macrolide antibiotics have demonstrated great benefit when used for their anti-inflammatory or immunomodulatory properties, which include the blockage of pro-inflammatory cytokines, such as interleukin (IL)-8 and tumor necrosis factor-α (TNF-α). They have been used in CRS patients not responding to traditional corticosteroid-based treatment regimens, but appear to be most effective specifically in Th1-mediated non-eosinophilic CRS in long durations and low doses. Further research is needed to better identify characteristics known to correlate with macrolide response so early directed therapy can be implemented. |
| doi_str_mv | 10.1007/s11882-017-0696-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891132742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1891132742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-7c4ecd9d1221e974887ca73780033f27c3f85982df3c91dfaf7ae35278ffeb5a3</originalsourceid><addsrcrecordid>eNp1kM1KAzEURoMotlYfwI0E3NTFaHIz0yRLqb9Qa6l1HdJMYlOmM3XSQezTm9IqIrjKhZzvu8lB6JSSS0oIvwqUCgEJoTwhPdlL1nuoTTOWJj1Gs_3NDDLhDKCFjkKYEwIxBYeoBSIFyUjWRjeTmcXjqrC4cvhJm7oqfG4D9iXuz-qq9AaPZ76sgi-b4Fc-4G5__BKGI6zLHMfxYzi6OEYHThfBnuzODnq9u530H5LB8_1j_3qQmJSJVcJNak0ucwpAreSpENxozrgghDEH3DAnMikgd8xImjvtuLYsAy6cs9NMsw7qbnuXdfXe2LBSCx-MLQpd2qoJigpJKQOeQkTP_6DzqqnL-LoNReJG4DJSdEvFf4dQW6eWtV_o-lNRojaK1VaxiorVRrFax8zZrrmZLmz-k_h2GgHYAiFelW-2_rX639YvO1OEZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1890003279</pqid></control><display><type>article</type><title>The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Oakley, Gretchen M. ; Harvey, Richard J. ; Lund, Valerie J.</creator><creatorcontrib>Oakley, Gretchen M. ; Harvey, Richard J. ; Lund, Valerie J.</creatorcontrib><description>Purpose of Review
We assess the literature on the pharmacokinetics, indications, important considerations, and effectiveness of long-term, low-dose macrolide antibiotics in chronic rhinosinusitis (CRS).
Recent Findings
The key to effective implementation of macrolide therapy in CRS is appropriate patient selection. Macrolides have demonstrated the most benefit in Th1-mediated non-eosinophilic CRS when used for durations of at least 3 months.
Summary
Macrolide antibiotics have demonstrated great benefit when used for their anti-inflammatory or immunomodulatory properties, which include the blockage of pro-inflammatory cytokines, such as interleukin (IL)-8 and tumor necrosis factor-α (TNF-α). They have been used in CRS patients not responding to traditional corticosteroid-based treatment regimens, but appear to be most effective specifically in Th1-mediated non-eosinophilic CRS in long durations and low doses. Further research is needed to better identify characteristics known to correlate with macrolide response so early directed therapy can be implemented.</description><identifier>ISSN: 1529-7322</identifier><identifier>EISSN: 1534-6315</identifier><identifier>DOI: 10.1007/s11882-017-0696-z</identifier><identifier>PMID: 28429305</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Allergology ; Antibiotics ; Chronic Disease ; Humans ; Macrolides - therapeutic use ; Medicine ; Medicine & Public Health ; Rhinitis ; Rhinitis - drug therapy ; Rhinitis - pathology ; Rhinosinusitis (J Mullol ; Section Editor ; Sinusitis ; Sinusitis - drug therapy ; Sinusitis - pathology ; Topical Collection on Rhinosinusitis ; Tumor necrosis factor-TNF</subject><ispartof>Current allergy and asthma reports, 2017-05, Vol.17 (5), p.30-30, Article 30</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Current Allergy and Asthma Reports is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-7c4ecd9d1221e974887ca73780033f27c3f85982df3c91dfaf7ae35278ffeb5a3</citedby><cites>FETCH-LOGICAL-c438t-7c4ecd9d1221e974887ca73780033f27c3f85982df3c91dfaf7ae35278ffeb5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11882-017-0696-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11882-017-0696-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28429305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oakley, Gretchen M.</creatorcontrib><creatorcontrib>Harvey, Richard J.</creatorcontrib><creatorcontrib>Lund, Valerie J.</creatorcontrib><title>The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP)</title><title>Current allergy and asthma reports</title><addtitle>Curr Allergy Asthma Rep</addtitle><addtitle>Curr Allergy Asthma Rep</addtitle><description>Purpose of Review
We assess the literature on the pharmacokinetics, indications, important considerations, and effectiveness of long-term, low-dose macrolide antibiotics in chronic rhinosinusitis (CRS).
Recent Findings
The key to effective implementation of macrolide therapy in CRS is appropriate patient selection. Macrolides have demonstrated the most benefit in Th1-mediated non-eosinophilic CRS when used for durations of at least 3 months.
Summary
Macrolide antibiotics have demonstrated great benefit when used for their anti-inflammatory or immunomodulatory properties, which include the blockage of pro-inflammatory cytokines, such as interleukin (IL)-8 and tumor necrosis factor-α (TNF-α). They have been used in CRS patients not responding to traditional corticosteroid-based treatment regimens, but appear to be most effective specifically in Th1-mediated non-eosinophilic CRS in long durations and low doses. Further research is needed to better identify characteristics known to correlate with macrolide response so early directed therapy can be implemented.</description><subject>Allergology</subject><subject>Antibiotics</subject><subject>Chronic Disease</subject><subject>Humans</subject><subject>Macrolides - therapeutic use</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Rhinitis</subject><subject>Rhinitis - drug therapy</subject><subject>Rhinitis - pathology</subject><subject>Rhinosinusitis (J Mullol</subject><subject>Section Editor</subject><subject>Sinusitis</subject><subject>Sinusitis - drug therapy</subject><subject>Sinusitis - pathology</subject><subject>Topical Collection on Rhinosinusitis</subject><subject>Tumor necrosis factor-TNF</subject><issn>1529-7322</issn><issn>1534-6315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kM1KAzEURoMotlYfwI0E3NTFaHIz0yRLqb9Qa6l1HdJMYlOmM3XSQezTm9IqIrjKhZzvu8lB6JSSS0oIvwqUCgEJoTwhPdlL1nuoTTOWJj1Gs_3NDDLhDKCFjkKYEwIxBYeoBSIFyUjWRjeTmcXjqrC4cvhJm7oqfG4D9iXuz-qq9AaPZ76sgi-b4Fc-4G5__BKGI6zLHMfxYzi6OEYHThfBnuzODnq9u530H5LB8_1j_3qQmJSJVcJNak0ucwpAreSpENxozrgghDEH3DAnMikgd8xImjvtuLYsAy6cs9NMsw7qbnuXdfXe2LBSCx-MLQpd2qoJigpJKQOeQkTP_6DzqqnL-LoNReJG4DJSdEvFf4dQW6eWtV_o-lNRojaK1VaxiorVRrFax8zZrrmZLmz-k_h2GgHYAiFelW-2_rX639YvO1OEZQ</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Oakley, Gretchen M.</creator><creator>Harvey, Richard J.</creator><creator>Lund, Valerie J.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP)</title><author>Oakley, Gretchen M. ; Harvey, Richard J. ; Lund, Valerie J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-7c4ecd9d1221e974887ca73780033f27c3f85982df3c91dfaf7ae35278ffeb5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Allergology</topic><topic>Antibiotics</topic><topic>Chronic Disease</topic><topic>Humans</topic><topic>Macrolides - therapeutic use</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Rhinitis</topic><topic>Rhinitis - drug therapy</topic><topic>Rhinitis - pathology</topic><topic>Rhinosinusitis (J Mullol</topic><topic>Section Editor</topic><topic>Sinusitis</topic><topic>Sinusitis - drug therapy</topic><topic>Sinusitis - pathology</topic><topic>Topical Collection on Rhinosinusitis</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oakley, Gretchen M.</creatorcontrib><creatorcontrib>Harvey, Richard J.</creatorcontrib><creatorcontrib>Lund, Valerie J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current allergy and asthma reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oakley, Gretchen M.</au><au>Harvey, Richard J.</au><au>Lund, Valerie J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP)</atitle><jtitle>Current allergy and asthma reports</jtitle><stitle>Curr Allergy Asthma Rep</stitle><addtitle>Curr Allergy Asthma Rep</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>17</volume><issue>5</issue><spage>30</spage><epage>30</epage><pages>30-30</pages><artnum>30</artnum><issn>1529-7322</issn><eissn>1534-6315</eissn><abstract>Purpose of Review
We assess the literature on the pharmacokinetics, indications, important considerations, and effectiveness of long-term, low-dose macrolide antibiotics in chronic rhinosinusitis (CRS).
Recent Findings
The key to effective implementation of macrolide therapy in CRS is appropriate patient selection. Macrolides have demonstrated the most benefit in Th1-mediated non-eosinophilic CRS when used for durations of at least 3 months.
Summary
Macrolide antibiotics have demonstrated great benefit when used for their anti-inflammatory or immunomodulatory properties, which include the blockage of pro-inflammatory cytokines, such as interleukin (IL)-8 and tumor necrosis factor-α (TNF-α). They have been used in CRS patients not responding to traditional corticosteroid-based treatment regimens, but appear to be most effective specifically in Th1-mediated non-eosinophilic CRS in long durations and low doses. Further research is needed to better identify characteristics known to correlate with macrolide response so early directed therapy can be implemented.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28429305</pmid><doi>10.1007/s11882-017-0696-z</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1529-7322 |
| ispartof | Current allergy and asthma reports, 2017-05, Vol.17 (5), p.30-30, Article 30 |
| issn | 1529-7322 1534-6315 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891132742 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Allergology Antibiotics Chronic Disease Humans Macrolides - therapeutic use Medicine Medicine & Public Health Rhinitis Rhinitis - drug therapy Rhinitis - pathology Rhinosinusitis (J Mullol Section Editor Sinusitis Sinusitis - drug therapy Sinusitis - pathology Topical Collection on Rhinosinusitis Tumor necrosis factor-TNF |
| title | The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T22%3A08%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Macrolides%20in%20Chronic%20Rhinosinusitis%20(CRSsNP%20and%20CRSwNP)&rft.jtitle=Current%20allergy%20and%20asthma%20reports&rft.au=Oakley,%20Gretchen%20M.&rft.date=2017-05-01&rft.volume=17&rft.issue=5&rft.spage=30&rft.epage=30&rft.pages=30-30&rft.artnum=30&rft.issn=1529-7322&rft.eissn=1534-6315&rft_id=info:doi/10.1007/s11882-017-0696-z&rft_dat=%3Cproquest_cross%3E1891132742%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1890003279&rft_id=info:pmid/28429305&rfr_iscdi=true |